机器人胰腺切除联合血管重建临床分析

摘要/Abstract

摘要：目的探讨机器人胰腺切除联合血管重建的安全性及可行性。方法回顾性分析2012年6月至2017年10月我院施行的15例机器人胰腺切除联合血管重建手术病人。8例胰十二指肠切除联合门静脉/肠系膜上静脉重建,1例胰十二指肠切除联合变异右肝动脉重建,2例胰体尾切除联合门静脉重建,2例胰体尾切除联合肝总动脉重建,2例全胰切除联合门静脉或肠系膜上静脉重建。结果15例机器人胰腺切除联合血管重建手术时间（343+80）（210~540) min。术中出血量(573+310)(200~1 100） mL。术后住院时间（29.8+27.7）（14~122） d。2例（13.3%）病人术后出现胰漏,无死亡病例。结论机器人胰腺切除联合血管重建安全可行,需手术医师有丰富经验和技术支持。

关键词:机器人手术,胰腺外科,血管重建

Abstract:ObjectiveTo evaluate the safety and feasibility of robotic pancreatectomy with vascular reconstruction.MethodsThe data of 15 patients who underwent robotic pancreatectomy combined with vascular reconstruction were reviewed. There were 8 cases of pancreatoduodenectomy with portal vein (PV) and superior mesenteric vein reconstruction. One case had pancreatoduodenectomy with variant right hepatic artery reconstruction. Four cases had distal pancreatectomy including 2 case with PV reconstruction and 2 cases with common hepatic artery reconstruction. Two cases had total pancreatectomy with PV or SMV reconstruction.ResultsThe operative time was (343+80)(210-540) min with blood loss (573+310)(200-1 100) mL. The postoperative hospital stay was (29.8+27.7)(14-122) d. Pancreatic fistula occurred in 2 cases (13.3%) without mortality.ConclusionsRobotic pancreatectomy with vascular reconstruction could be safe and feasible, however, extensive experience with technical support should be needed.

Key words:Robotic surgery,Pancreatic surgery,Vascular reconstruction

中图分类号:

R735.9

孙长杰, 邓侠兴, 沈柏用, 彭承宏. 机器人胰腺切除联合血管重建临床分析[J]. 外科理论与实践, 2019, 24(02): 159-162.

SUN Changjie, DENG Xiaxing, SHEN Bai-yong, PENG Chenghong. Clinical study of robotic pancreatectomy with vascular reconstruction[J]. Journal of Surgery Concepts & Practice, 2019, 24(02): 159-162.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015[J]. CA Cancer J Clin,2015,65(1):5-29.
[2] Kendrick ML.Laparoscopic and robotic resection for pancreatic cancer[J]. Cancer J,2012,18(6):571-576.
[3] Sadot E, Doussot A, O′Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma[J]. Ann Surg Oncol,2015,22(11):3512-3521.
[4] Boone BA, Steve J, Krasinskas AM, et al.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer[J]. J Surg Oncol,2013,108(4):236-241.
[5] Evans DB, Varadhachary GR, Crane CH, et al.Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol,2008,26(21):3496-3502.
[6] Varadhachary GR, Wolff RA, Crane CH, et al.Preope-rative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head[J]. J Clin Oncol,2008,26(21):3487-3495.
[7] Katz MH, Pisters PW, Evans DB, et al.Borderline resectable pancreatic cancer: the importance of this emer-ging stage of disease[J]. J Am Coll Surg,2008,206(5):833-848.
[8] Ferrone CR, Marchegiani G, Hong TS, et al.Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg,2015,261(1):12-17.
[9] Blazer M, Wu C, Goldberg RM, et al.Neoadjuvant modified (m)FOLFIRINOX for locally advancedunresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas[J]. Ann Surg Oncol,2015,22(4):1153-1159.
[10] Chen S, Chen JZ, Zhan Q, et al.Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study[J]. Surg Endosc,2015,29(12):3698-3711.
[11] Chen S, Zhan Q, Chen JZ, et al.Robotic approach improves spleen-preserving rate and shortens postoperative hospital stay of laparoscopic distal pancreatectomy: a matched cohort study[J]. Surg Endosc,2015,29(12):3507-3518.
[12] Al-Haddad M, Martin JK, Nguyen J, et al.Vascular resection and reconstruction for pancreatic malignancy: a single center survival study[J]. J Gastrointest Surg,2007, 11(9):1168-1174.
[13] Fortner JG.Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results[J]. Ann Surg,1984,199(4):418-425.
[14] Evans DB, Farnell MB, Lillemoe KD, et al.Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement[J]. Ann Surg Oncol,2009,16(7):1736-1744.
[15] Tseng JF, Tamm EP, Lee JE, et al.Venous resection in pancreatic cancer surgery[J]. Best Pract Res,2006,20(2):349-364.
[16] Riediger H, Makowiec F, Fischer E, et al.Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection[J]. J Gastrointest Surg,2006,10(8):1106-1115.
[17] Ramacciato G, Mercantini P, Petrucciani N, et al.Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma?[J]. Ann Surg Oncol,2009,16(4):817-825.
[18] Gagandeep S, Artinyan A, Jabbour N, et al.Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation[J]. Am J Surg,2006,192(3):330-335.
[19] Giulianotti PC, Coratti A, Angelini M, et al.Robotics in general surgery: personal experience in a large community hospital[J]. Arch Surg,2003,138(7):777-784.
[20] Giulianotti PC, Addeo P, Buchs NC, et al.Robotic extended pancreatectomy with vascular resection for locally advanced pancreatic tumors[J]. Pancreas,2011,40(8):1264-1270.
[21] Daouadi M, Zureikat AH, Zenati MS, et al.Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique[J]. Ann Surg,2013,257(1):128-132.
[22] Zureikat AH, Moser AJ, Boone BA, et al.250 robotic pancreatic resections: safety and feasibility[J]. Ann Surg,2013,258(4):554-562.
[23] Dua MM, Tran TB, Klausner J, et al.Pancreatectomy with vein reconstruction: technique matters[J]. HPB(Oxford),2015,17(9):824-831.
[24] Khatkov IE, Izrailov RE, Khisamov AA, et al.Superior mesenteric-portal vein resection during laparoscopic pancreatoduodenectomy[J]. Surg Endosc,2017,31(3):1488-1495.